Anavex Life Sciences (AVXL) Stock Price, News & Analysis

Company Overview

Anavex Life Sciences Corp. (NASDAQ: AVXL) is a clinical-stage biotechnology company focused on developing pharmaceutical therapies for central nervous system disorders. The company’s research is centered on small-molecule compounds intended to address cellular pathways associated with neurodegeneration and other neurological conditions.

Anavex’s lead product candidate is blarcamesine (ANAVEX2-73), an orally administered investigational therapy designed to activate the sigma-1 receptor and modulate muscarinic receptors. The company has evaluated blarcamesine in clinical studies for Alzheimer’s disease, Rett syndrome and Parkinson’s disease dementia. Anavex is also developing additional investigational compounds, including ANAVEX3-71, for potential use in neurodegenerative diseases. These candidates have not been approved as treatments by regulatory authorities.

Founded in 2006, Anavex Life Sciences conducts research and clinical development activities through collaborations and trials in multiple regions, including the United States, Australia and Europe. The company is led by Christopher U. Missling, Ph.D., who serves as president and chief executive officer.

Key Stats

• Today's Range: $1.44 to $1.54
• 50-Day Range: $1.49 to $3.56
• 52-Week Range: $1.44 to $9.53
• Volume: 1.29 million shs
• Average Volume: 1.20 million shs
• Market Capitalization: $138.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.33
• Consensus Rating: Hold

Anavex Life Sciences Stock Analysis - MarketRank™

Anavex Life Sciences scored higher than 33% of companies evaluated by MarketBeat, and ranked 789th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Anavex Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Anavex Life Sciences has a consensus price target of $21.33, representing about 1,331.8% upside from its current price of $1.49.

Amount of Analyst Coverage

Anavex Life Sciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Anavex Life Sciences are expected to decrease in the coming year, from ($0.33) to ($0.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Anavex Life Sciences is -9.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Anavex Life Sciences is -9.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Anavex Life Sciences has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.52% of the float of Anavex Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Anavex Life Sciences has a short interest ratio ("days to cover") of 13.56, which indicates bearish sentiment.

Change versus previous month

Short interest in Anavex Life Sciences has recently decreased by 5.35%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Anavex Life Sciences does not currently pay a dividend.

Dividend Growth

Anavex Life Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 1.2 / 5
• News Sentiment: -0.08

News Sentiment

Anavex Life Sciences has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 26 news articles for Anavex Life Sciences this week, compared to 5 articles on an average week.

MarketBeat Follows

Only 2 people have added Anavex Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Anavex Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.40% of the stock of Anavex Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

31.55% of the stock of Anavex Life Sciences is held by institutions.

Company Calendar

• Last Earnings: 8/25/2026
• Today: 10/09/2026
• Next Earnings (Estimated): 11/24/2026
• Fiscal Year End: 9/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AVXL
• CIK: 1314052
• Web: www.anavex.com
• Phone: (844) 689-3939
• Fax: N/A
• Employees: 34
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Anavex Life Sciences: $21.33
• High Price Target: $24.00
• Low Price Target: $20.00
• Potential Upside/Downside: +1,331.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$46.38 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -11.43%
• Return on Assets: -10.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.62
• Quick Ratio: 15.62

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.10 per share
• Price / Book: 1.35

Miscellaneous

• Outstanding Shares: 92,700,000
• Free Float: 82,130,000
• Market Cap: $138.12 million
• Optionable: Optionable
• Beta: 1.17